KBTBD8 Inhibitors
Chemical inhibitors of KBTBD8 operate through various mechanisms to interfere with the protein's function by targeting specific cellular processes and signaling pathways that are essential for its activity. Alsterpaullone and Roscovitine, for instance, are inhibitors of cyclin-dependent kinases (CDKs), a group of proteins that play a pivotal role in cell cycle regulation. By inhibiting CDKs, these chemicals impair the cell cycle control mechanisms, which are intrinsically linked to the role of KBTBD8 in protein degradation during neural crest formation. This disruption of cell cycle phases translates into a functional inhibition of KBTBD8, as it is unable to execute its role effectively in the absence of proper cell cycle progression.
Furthermore, a group of chemicals including Sotrastaurin, Go6983, Bisindolylmaleimide I, Chelerythrine, Ruboxistaurin, Midostaurin, Ro-31-8220, Enzastaurin, Staurosporine, and K252a, target the protein kinase C (PKC) family. KBTBD8 is involved in pathways that are regulated by PKC, which is crucial for modulating various cellular functions, including cytoskeletal organization and signal transduction. These inhibitors, by targeting PKC, alter the phosphorylation status of substrates within the cell, leading to a disruption of the normal signaling cascades. Since KBTBD8's activity is contingent upon these pathways, the inhibition of PKC effectively results in the functional inhibition of KBTBD8. The altered signaling dynamics consequent to PKC inhibition create a cellular environment where KBTBD8 cannot contribute to its usual processes, thereby reducing its functional impact within the cell.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $67.00 $306.00 | 2 | |
Alsterpaullone is a known inhibitor of cyclin-dependent kinases (CDKs). KBTBD8 is involved in regulating protein degradation during neural crest formation, a process that is tightly linked to the cell cycle. By inhibiting CDKs, alsterpaullone would disrupt the cell cycle control, thereby functionally inhibiting KBTBD8's role in this process. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $92.00 $260.00 | 42 | |
Roscovitine specifically inhibits CDKs, which are crucial for cell cycle progression. Since KBTBD8 has a role in cell cycle-associated protein degradation, inhibiting CDKs would impair the cell cycle phases critical for KBTBD8's function, thereby functionally inhibiting the protein. | ||||||
Sotrastaurin | 425637-18-9 | sc-474229 sc-474229A | 5 mg 10 mg | $300.00 $540.00 | ||
Sotrastaurin is a selective inhibitor of protein kinase C (PKC). KBTBD8 is implicated in pathways involving PKC, which modulates cytoskeletal organization. Inhibiting PKC would alter the cytoskeletal dynamics, indirectly functionally inhibiting KBTBD8 activity related to cellular structure organization. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $103.00 $293.00 $465.00 | 15 | |
Go6983 is a pan-PKC inhibitor. By inhibiting PKC, it would disrupt PKC-mediated signaling required for processes in which KBTBD8 is involved, leading to the functional inhibition of KBTBD8. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
Bisindolylmaleimide I is another PKC inhibitor. It would prevent PKC from phosphorylating its substrates, which is necessary for the regulation of activities in which KBTBD8 is implicated, thus functionally inhibiting KBTBD8. | ||||||
Chelerythrine chloride | 3895-92-9 | sc-3547 sc-3547A | 5 mg 25 mg | $88.00 $311.00 | 17 | |
Chelerythrine is a selective inhibitor of PKC. By inhibiting PKC, chelerythrine would interfere with the signaling pathways involving PKC, where KBTBD8 plays a role, resulting in the functional inhibition of KBTBD8. | ||||||
Ruboxistaurin | 169939-94-0 | sc-507364 | 25 mg | $1080.00 | ||
Ruboxistaurin selectively inhibits PKCβ. Since KBTBD8 functions in pathways that are regulated by PKC, inhibition of PKCβ would disrupt these pathways, leading to the functional inhibition of KBTBD8's activity. | ||||||
Ro 31-8220 | 138489-18-6 | sc-200619 sc-200619A | 1 mg 5 mg | $90.00 $240.00 | 17 | |
Ro-31-8220 is a potent PKC inhibitor. It would inhibit PKC activity, thereby disrupting the phosphorylation events necessary for the functions mediated by KBTBD8, leading to its functional inhibition. | ||||||
Enzastaurin | 170364-57-5 | sc-364488 sc-364488A sc-364488B | 10 mg 50 mg 200 mg | $254.00 $600.00 $1687.00 | 3 | |
Enzastaurin is a PKCβ inhibitor. It would disrupt signaling pathways involving PKCβ, which are essential for KBTBD8's function, thereby causing functional inhibition of KBTBD8. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a broad-spectrum kinase inhibitor, which includes inhibition of PKC. By broadly inhibiting kinases including PKC, it would interfere with signaling essential for KBTBD8 function, resulting in functional inhibition of the protein. | ||||||